201 related articles for article (PubMed ID: 30233377)
1.
Lattanzi R; Rief S; Schmidhammer H; Negri L; Spetea M
Front Pharmacol; 2018; 9():1002. PubMed ID: 30233377
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor function.
Spetea M; Bohotin CR; Asim MF; Stübegger K; Schmidhammer H
Eur J Pharm Sci; 2010 Sep; 41(1):125-35. PubMed ID: 20600882
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
4. Bioactivity of new mu and delta opioid peptides.
Capasso A
Med Chem; 2007 Sep; 3(5):480-7. PubMed ID: 17897075
[TBL] [Abstract][Full Text] [Related]
5. Novel approach to demonstrate high efficacy of mu opioids in the rat vas deferens: a simple model of predictive value.
Riba P; Friedmann T; Király KP; Al-Khrasani M; Sobor M; Asim MF; Spetea M; Schmidhammer H; Furst S
Brain Res Bull; 2010 Jan; 81(1):178-84. PubMed ID: 19800397
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
[TBL] [Abstract][Full Text] [Related]
7. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.
Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA
Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
[TBL] [Abstract][Full Text] [Related]
9. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753.
Barber A; Bartoszyk GD; Bender HM; Gottschlich R; Greiner HE; Harting J; Mauler F; Minck KO; Murray RD; Simon M
Br J Pharmacol; 1994 Dec; 113(4):1317-27. PubMed ID: 7889287
[TBL] [Abstract][Full Text] [Related]
10. The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability.
Yi SP; Kong QH; Li YL; Pan CL; Yu J; Cui BQ; Wang YF; Wang GL; Zhou PL; Wang LL; Gong ZH; Su RB; Shen YH; Yu G; Chang KJ
Acta Pharmacol Sin; 2017 Jul; 38(7):977-989. PubMed ID: 28502978
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological mechanisms underlying the antinociceptive and tolerance effects of the 6,14-bridged oripavine compound 030418.
Wen Q; Yu G; Li YL; Yan LD; Gong ZH
Acta Pharmacol Sin; 2011 Oct; 32(10):1215-24. PubMed ID: 21863064
[TBL] [Abstract][Full Text] [Related]
12. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
13. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
[TBL] [Abstract][Full Text] [Related]
14. MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.
Matsumoto K; Takayama H; Narita M; Nakamura A; Suzuki M; Suzuki T; Murayama T; Wongseripipatana S; Misawa K; Kitajima M; Tashima K; Horie S
Neuropharmacology; 2008 Aug; 55(2):154-65. PubMed ID: 18550129
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
16. DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity.
Gengo PJ; Pettit HO; O'Neill SJ; Wei K; McNutt R; Bishop MJ; Chang KJ
J Pharmacol Exp Ther; 2003 Dec; 307(3):1221-6. PubMed ID: 14534368
[TBL] [Abstract][Full Text] [Related]
17. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic.
De Souza EB; Schmidt WK; Kuhar MJ
J Pharmacol Exp Ther; 1988 Jan; 244(1):391-402. PubMed ID: 2826773
[TBL] [Abstract][Full Text] [Related]
18. Thienorphine induces antinociception without dependence through activation of κ- and δ-, and partial activation of μ- opioid receptor.
Zhou P; Li Y; Yong Z; Chen M; Zhang Y; Su R; Gong Z
Brain Res; 2020 Dec; 1748():147083. PubMed ID: 32871137
[TBL] [Abstract][Full Text] [Related]
19. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
[TBL] [Abstract][Full Text] [Related]
20. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor.
Matthes HW; Smadja C; Valverde O; Vonesch JL; Foutz AS; Boudinot E; Denavit-Saubié M; Severini C; Negri L; Roques BP; Maldonado R; Kieffer BL
J Neurosci; 1998 Sep; 18(18):7285-95. PubMed ID: 9736649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
